Harnessing the Power of the Microbiome
Rebiotix Inc., a Ferring Company, is based in Roseville, Minnesota. We were founded in 2011 on the belief that the power of the microbiome could be harnessed to treat debilitating diseases. Today, we are proud to extend that mission globally, ensuring that the future of microbiome-based technologies will remain focused on some of the greatest healthcare challenges of our time.
Ferring Pharmaceuticals: The Global Leader in Microbiome-Based Therapeutics and Research
Ferring Pharmaceuticals is a globally-recognized specialty pharmaceutical company driven to help people live better lives. The company’s strong history and passion for microbiome-based technologies, combined with our leading expertise and research platform, led to the FDA’s approval of a first-in-class live biotherapeutic product in the US for the prevention of C. difficile infection recurrence. Additionally, our field leadership sets the stage for new and innovative technologies to reach patients, physicians and families everywhere.
For more information about Ferring Pharmaceuticals and our work in the microbiome field, we invite you to visit the following links:
- For US-based enquiries, please visit ferringUSA.com
- For more information regarding recurrent C. difficile infection, please visit Ferring’s resource page.
- For enquiries outside of the United States, please visit ferring.com
For those interested in our stool donor program, we invite you to visit our Donor Program page for additional information.
For those interested in joining our team, please visit our Careers page for our most recent available openings.
Key Milestones in Harnessing the Power of the Human Microbiome
-
Rebiotix was founded
2011
-
Pre-Investigational New Drug (IND) meeting with FDA for live biotherapeutic product candidate RBX2660
2012
-
FDA IND granted
Fast Track designation granted
PUNCH CD Phase 2 trial enrolled for RBX2660 for recurrent Clostridioides difficile infection
2013
-
FDA Orphan Drug designation granted
Results of PUNCH CD announced
PUNCH CD 2 (phase 2b) trial initiated for recurrent Clostridioides difficile infection
2014
-
PUNCH CD 2 enrollment completed
PUNCH CD2 Open Label Study initiated for recurrent Clostridioides difficile infection
FDA Breakthrough Therapy Status granted for RBX2660
Oral formulation Drug Master File (DMF) filed with FDA
2015
-
PUNCH CD 2 Randomized Double Blind Placebo Control Study results announced
RBX7455 Non-Frozen Capsule feasibility study initiated
2016
-
Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridioides difficile
Phase 3 PUNCH CD3 initiated Q3 2017 for recurrent Clostridioides difficile infection
2017
-
Ferring acquires Rebiotix in April
2018
-
Phase 3 Open Label PUNCH CD3-OLS Initiated Q2 2019 for recurrent Clostridioides difficile infection
2019
-
Phase 3 PUNCH CD3 Enrollment Completed
Phase 3 PUNCH CD3 Positive Topline Results Announced
2020
-
Phase 3 PUNCH CD3 Data presented at DDW 2021
Phase 3 Open Label PUNCH CD3-OLS Interim Results presented at DDW 2021
2021
-
FDA Advisory Committee held to assess potential lead live biotherapeutic candidate RBX2660
FDA Approves REBYOTA™ (fecal microbiota, live-jslm) as first-in-class therapeutic for the prevention of Recurrence of Clostridioides difficile infection in adults
2022